Lymphoma Clinical Trials

Showing 1581-1600 of 2,926 trials

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

NCT04264078

The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen receptor)-T cell therapies are efficient for patients with B-cell hematologic malignancies. As for T-cell hematologic malignancies, CD7 is a promising target expressed on most malignant T cells. The outcome of CD-7 CAR-T cell therapy pre-clinical experiments is cheerful.however, how to select the functional T cells from the malignant T cells is a challenge. In addition to this, auto-CAR-T cell therapy is not affordable for the majority of patients. Using T cells aphesis from healthy donors edited to avoid rejection of the host as the material of anti-CD7 universal CAR-T cells could be accessible and affordable, which is adapted for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies.

T-cell LeukemiaT-cell Lymphoma

Xinqiao Hospital of Chongqing30 participantsStarted Mar 2021

Chongqing, Chongqing Municipality, China

UNKNOWNPhase 1

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

NCT04934774

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T cell lymphoma or leukemia

T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-cell Non-Hodgkin Lymphoma

iCell Gene Therapeutics20 participantsStarted Dec 2020

Shenzhen, Guangdong, China

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

Related Searches

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma

High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant

CD19-Specific T Cells Post AlloSCT

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study